Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study

Abstract : Genomic alterations play a crucial role in the development and progression of diffuse large B-cell lymphomas (DLBCLs). We determined gene copy number alterations (GCNAs) of TP53, CDKN2A, CDKN1B, BCL2, MYC, REL, and RB1 with a single polymerase chain reaction (PCR) assay (quantitative multiplex PCR of short fragments [QMPSF]) in a cohort of 114 patients with DLBCL to assess their prognostic value and relationship with the gene expression profile. Losses of TP53 and CDKN2A, observed in 8% and 35% of patients, respectively, were significantly associated with a shorter survival after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treatment, independently of the International Prognostic Index and of the cell of origin. Analysis of the 9p21 genomic region indicated that transcripts encoding p14ARF and p16INK4A were both disrupted in most patients with CDKN2A deletion. These patients predominantly had an activated B-cell profile and showed a specific gene expression signature, characterized by dysregulation of the RB/E2F pathway, activation of cellular metabolism, and decreased immune and inflammatory responses. These features may constitute the molecular basis sustaining the unfavorable outcome and chemoresistance of this DLBCL subgroup. Detection of TP53 and CDKN2A loss by QMPSF is a powerful tool that could be used for patient stratification in future clinical trials.
Type de document :
Article dans une revue
Blood, American Society of Hematology, 2010, 116 (7), pp.1092-1104. 〈10.1182〉
Liste complète des métadonnées

https://hal-ens-lyon.archives-ouvertes.fr/ensl-00816038
Contributeur : Agnès Ganivet <>
Soumis le : vendredi 19 avril 2013 - 16:14:04
Dernière modification le : mardi 5 juin 2018 - 10:14:25

Identifiants

  • HAL Id : ensl-00816038, version 1
  • DOI : 10.1182

Citation

Fabrice Jardin, Jean-Philippe Jais, Thierry-Jo Molina, Françoise Parmentier, Jean-Michel Picquenot, et al.. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Blood, American Society of Hematology, 2010, 116 (7), pp.1092-1104. 〈10.1182〉. 〈ensl-00816038〉

Partager

Métriques

Consultations de la notice

279